Pigmentation Disorders Treatment: Global Strategic Business Report

Global Pigmentation Disorders Treatment Market to Reach $10.1 Billion by 2030

The global market for Pigmentation Disorders Treatment estimated at US$6.5 Billion in the year 2022, is projected to reach a revised size of US$10.1 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2022-2030. Topical Drugs, one of the segments analyzed in the report, is projected to record 6.7% CAGR and reach US$4.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Laser Therapy segment is readjusted to a revised 5.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 8.8% CAGR

The Pigmentation Disorders Treatment market in the U.S. is estimated at US$1.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Select Competitors (Total 41 Featured) -

• Allergan PLC
• Bayer AG
• Epipharm AG
• Galderma SA
• Obagi Cosmeceuticals LLC (Obagi Medical)
• Pierre Fabre SA
• RXi Pharmaceuticals Corporation
• SkinCeuticals
• Vivier Pharma, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year